
<!DOCTYPE html>
<html>
    <head>
        <title>【中泰医药谢木青/于佳喜】持续推荐迪安诊断：业绩超预期，ICL龙头持续快速增长</title>
        <meta charset="utf-8" />
    </head>
    <body>
        <div class="note-wrapper">
            <h1>【中泰医药谢木青/于佳喜】持续推荐迪安诊断：业绩超预期，ICL龙头持续快速增长</h1>
			<button class="btn btn-primary"><a href="../index.html">返回主页</a></button><br><br>
			【中泰医药谢木青/于佳喜】持续推荐迪安诊断：业绩超预期，ICL龙头持续快速增长<br><br>常规ICL稳定增长，核酸检测贡献良好现金流。2022Q2公司预计实现归母8.46-11.46亿元（+117.8%-195.0%），在新冠疫情反复、诊疗活动尚未完全复苏的条件下实现超预期表现。公司常规ICL业务顺应医改降本控费政策趋势，具备较强抗风险能力，预计22H1常规ICL或将保持10-20%增长。新冠检测方面，国内防控形势依旧严峻，常态化核酸陆续扩面，预计22Q2核酸检测收入规模有望进一步扩大，但政府指导价持续下调可能影响公司新冠检验价格，导致新冠利润率降低，我们预计核酸检测或将贡献稳定现金流。<br><br>临床质谱进入收获阶段，自产产品业务有望延续近年来快速增长趋势。公司构筑了质谱诊断、分子诊断、细胞病理三大自主产品线，其中特色质谱业务已形成高端仪器+试剂的全面布局，是国内临床质谱产品的领头羊，公司自产产品业务具备较高成长空间。<br><br>长期向好趋势不变，龙头ICL有望持续快速增长。第三方医学检验顺应国家政策导向以及行业未来趋势，有望帮助医院检验科降本控费，实现外包率提升，龙头ICL的规模效应和综合服务能力优势将越发凸显，公司有望在中长期内保持快速增长。<br><br>盈利预测与投资建议：预计2022年-2024年公司收入172.79、163.51、169.45亿元（+32%、-5%、4%），实现归母净利润24.90、20.50、21.47亿元（+114%、-18%、5%）。<br><br>风险提示事件：实验室盈利时间不确定等<br><br>#文字纪要#
            <br><br><button class="btn btn-primary"><a href="../index.html">返回主页</a></button>

        </div>
        <script type="text/javascript">
            (function() {

    var doc_ols = document.getElementsByTagName("ol");

    for ( i=0; i<doc_ols.length; i++) {

        var ol_start = doc_ols[i].getAttribute("start") - 1;
        doc_ols[i].setAttribute("style", "counter-reset:ol_counter " + ol_start + ";");

    }

})();

        </script>
        <style>
            html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr,th,td,article,aside,canvas,details,embed,figure,figcaption,footer,header,hgroup,menu,nav,output,ruby,section,summary,time,mark,audio,video{margin:0;padding:0;border:0;font:inherit;font-size:100%;vertical-align:baseline}html{line-height:1}ol,ul{list-style:none}table{border-collapse:collapse;border-spacing:0}caption,th,td{text-align:left;font-weight:normal;vertical-align:middle}q,blockquote{quotes:none}q:before,q:after,blockquote:before,blockquote:after{content:"";content:none}a img{border:none}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}*{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}html{font-size:87.5%;line-height:1.57143em}html{font-size:14px;line-height:1.6em;-webkit-text-size-adjust:100%}body{background:#fcfcfc;color:#545454;text-rendering:optimizeLegibility;font-family:"AvenirNext-Regular"}a{color:#de4c4f;text-decoration:none}h1{font-family:"AvenirNext-Medium";color:#333;font-size:1.6em;line-height:1.3em;margin-bottom:.78571em}h2{font-family:"AvenirNext-Medium";color:#333;font-size:1.3em;line-height:1em;margin-bottom:.62857em}h3{font-family:"AvenirNext-Medium";color:#333;font-size:1.15em;line-height:1em;margin-bottom:.47143em}p{margin-bottom:1.57143em;hyphens:auto}hr{height:1px;border:0;background-color:#dedede;margin:-1px auto 1.57143em auto}ul,ol{margin-bottom:.31429em}ul ul,ul ol,ol ul,ol ol{margin-bottom:0px}ol{counter-reset:ol_counter}ol li:before{content:counter(ol_counter) ".";counter-increment:ol_counter;color:#e06e73;text-align:right;display:inline-block;min-width:1em;margin-right:0.5em}b,strong{font-family:"AvenirNext-Bold"}i,em{font-family:"AvenirNext-Italic"}code{font-family:"Menlo-Regular"}.text-overflow-ellipsis{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.sf_code_string,.sf_code_selector,.sf_code_attr-name,.sf_code_char,.sf_code_builtin,.sf_code_inserted{color:#D33905}.sf_code_comment,.sf_code_prolog,.sf_code_doctype,.sf_code_cdata{color:#838383}.sf_code_number,.sf_code_boolean{color:#0E73A2}.sf_code_keyword,.sf_code_atrule,.sf_code_rule,.sf_code_attr-value,.sf_code_function,.sf_code_class-name,.sf_code_class,.sf_code_regex,.sf_code_important,.sf_code_variable,.sf_code_interpolation{color:#0E73A2}.sf_code_property,.sf_code_tag,.sf_code_constant,.sf_code_symbol,.sf_code_deleted{color:#1B00CE}.sf_code_macro,.sf_code_entity,.sf_code_operator,.sf_code_url{color:#920448}.note-wrapper{max-width:46em;margin:0px auto;padding:1.57143em 3.14286em}.note-wrapper.spotlight-preview{overflow-x:hidden}u{text-decoration:none;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#e06e73 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}s{color:#878787}p{margin-bottom:0.1em}hr{margin-bottom:0.7em;margin-top:0.7em}ul li{text-indent:-0.35em}ul li:before{content:"•";color:#e06e73;display:inline-block;margin-right:0.3em}ul ul{margin-left:1.25714em}ol li{text-indent:-1.45em}ol ol{margin-left:1.25714em}blockquote{display:block;margin-left:-1em;padding-left:0.8em;border-left:0.2em solid #e06e73}.todo-list ul{margin-left:1.88571em}.todo-list li{text-indent:-1.75em}.todo-list li:before{content:"";display:static;margin-right:0px}.todo-checkbox{text-indent:-1.7em}.todo-checkbox svg{margin-right:0.3em;position:relative;top:0.2em}.todo-checkbox svg #check{display:none}.todo-checkbox.todo-checked #check{display:inline}.todo-checkbox.todo-checked+.todo-text{text-decoration:line-through;color:#878787}.code-inline{display:inline;background:white;border:solid 1px #dedede;padding:0.2em 0.5em;font-size:0.9em}.code-multiline{display:block;background:white;border:solid 1px #dedede;padding:0.7em 1em;font-size:0.9em;overflow-x:auto}.hashtag{display:inline-block;color:white;background:#b8bfc2;padding:0.0em 0.5em;border-radius:1em;text-indent:0}.hashtag a{color:#fff}.address a{color:#545454;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#0da35e 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}.address svg{position:relative;top:0.2em;display:inline-block;margin-right:0.2em}.color-preview{display:inline-block;width:1em;height:1em;border:solid 1px rgba(0,0,0,0.3);border-radius:50%;margin-right:0.1em;position:relative;top:0.2em;white-space:nowrap}.color-code{margin-right:0.2em;font-family:"Menlo-Regular";font-size:0.9em}.color-hash{opacity:0.4}.ordered-list-number{color:#e06e73;text-align:right;display:inline-block;min-width:1em}.arrow svg{position:relative;top:0.08em;display:inline-block;margin-right:0.15em;margin-left:0.15em}.arrow svg #rod{stroke:#545454}.arrow svg #point{fill:#545454}mark{color:inherit;display:inline;padding:0.2em 0.5em;background-color:#fcffc0}img{max-width:100%;height:auto}
        </style>
    </body>
</html>
